Bicara Therapeutics initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst Judah Frommer initiated coverage of Bicara Therapeutics (BCAX) with an Overweight rating and $35 price target. The firm believes early clinical data for ficerafusp alfa “underscore a meaningful potential advancement” over standard of care therapy in recurrent/metastatic head and neck cancer. The company’s key competitor Merus (MRUS) provided valuation support as we await Bicara’s key 2027 data readout, the analyst tells investors in a research note.